Investors of ADMA Biologics Inc. Urged to Lead Class Action Lawsuit Against Company

ADMA Biologics Class Action Lawsuit

Overview of the Situation
Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors in ADMA Biologics, Inc. (NASDAQ: ADMA). Those who purchased or acquired publicly traded securities of the company between August 9, 2024, and March 25, 2026, are encouraged to lead a class action lawsuit against the company. The deadline for seeking the lead plaintiff role is August 10, 2026.

Details of the Class Action
The lawsuit, titled Mazzarino v. ADMA Biologics, Inc., involves serious allegations against ADMA Biologics and its top executives, including violations of the Securities Exchange Act of 1934. Complaints cite that throughout the designated Class Period, the defendants made misleading statements and failed to disclose critical information.

Among the allegations are:
1. Undisclosed Related Party Transactions: It is claimed that ADMA engaged in related party transactions that were not revealed to investors.
2. Channel Stuffing Practices: The class action suggests that ADMA Biologics utilized 'channel stuffing' to create a façade of revenue growth, thereby misleading investors about the company’s actual financial health.
3. Inadequate Internal Controls: Concerns have been raised about the company's internal controls, which allegedly did not meet acceptable standards.

On March 24, 2026, a revealing report by Culper Research highlighted these issues, stating that the supposed growth reported by ADMA was largely driven by deceptive practices, leading to a 16% decline in the company’s stock price. In subsequent news, ADMA's efforts to address these claims were deemed inadequate, culminating in further stock depreciation.

The Importance of the Lead Plaintiff
The Private Securities Litigation Reform Act of 1995 allows investors who have incurred losses during the Class Period to serve as lead plaintiffs. A lead plaintiff is pivotal in directing the class action lawsuit on behalf of all affected investors. Investors interested in being appointed can compile their information and may also seek legal counsel of their choice for representation. Herein lies a chance for victims of the alleged misconduct to potentially recover losses and demand accountability from ADMA Biologics.

Robbins Geller Rudman & Dowd LLP has established itself as a prominent player in securities fraud litigation, recovering significant sums for investors in the past. The firm has ranked first in recovering funds for investors, helping generate over $8.4 billion in the last five years.

Next Steps for Investors
Investors who believe they have substantial losses and wish to serve as lead plaintiff should contact Robbins Geller's attorneys Ken Dolitsky or Michael Albert at 800-851-7783, or visit their website to submit their information directly. With mounting pressures on ADMA Biologics and ongoing legal implications, this is a critical moment for investors looking for recourse. This class action represents not just potential recovery but a means to instigate much-needed changes in corporate governance and accountability at ADMA Biologics.

Conclusion
The upcoming August deadline emphasizes the urgency for affected investors to act. Engaging in this lawsuit can amplify their voices and bring forth a disciplined approach to corporate governance within biopharmaceutical companies like ADMA Biologics. Through collective action, investors can ensure their rights are upheld and demand transparency from the companies they support.